


MGRC Therapeutics and Twistcode Technologies Collaborate to Develop Advanced Bioinformatics Platform

PETALING JAYA, 6 MAY 2024 – [Malaysian Genomics Resource Centre Berhad](#) (“MGRC” or “the Group”), a leading genomics and biopharmaceutical specialist, is pleased to announce that their wholly-owned subsidiary **MGRC Therapeutics Sdn Bhd** (“MGRCT”) has entered a Memorandum of Understanding (“MoU”) with Twistcode Technologies Sdn Bhd (“Twistcode Technologies”). This collaboration will focus on the **Bioinformatics Enhanced-Accelerated Services Terminal (B.E.A.S.T)**, a cutting-edge platform designed to revolutionise bioinformatics services across Malaysia and the Middle East.

Under the terms of the MoU, MGRCT and Twistcode Technologies will explore collaborative opportunities in research, development, and commercialisation. The partnership is poised to develop advanced bioinformatics tools and integrate artificial intelligence to accelerate bioinformatics processes, ultimately fostering a one-stop solution for bioinformatics services.



Azri Azerai, Executive Chairman of Malaysian Genomics expressed his enthusiasm about the collaboration by saying, "We are thrilled to partner with Twistcode Technologies to leverage their expertise in supercomputing and AI. This collaboration is set to enhance our capabilities in genomics and biopharmaceuticals significantly. Together, we aim to set new benchmarks in bioinformatics, contributing to advancements in healthcare and precision medicine."

Nurazan Malim, Director of Twistcode Technologies said, "This MoU with MGRCT marks a significant milestone in our journey to harness the power of AI in healthcare. The B.E.A.S.T platform represents a major step forward in our commitment to innovation and excellence. We are confident that this collaboration will not only enhance our technological capabilities but also create substantial value for the bioinformatics community."

This strategic collaboration highlights MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies. By combining MGRC’s healthcare production capabilities with Twistcode Technologies’ computational expertise, this partnership is set to significantly advance the reach and effectiveness of bioinformatics services.

###

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, visit www.mgrc.com.my.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Malaysian Genomics Resource Centre Berhad

For more information, please contact:

Jazzmin Wan

Tel: +60 17-289 4110

Email: j.wan@swanconsultancy.biz

Xinyi Ching

Tel: +60 19-337 9099

Email: x.ching@swanconsultancy.biz
